75/100 B+ · Critical risk
1 serious risk flag found TraceComp due-diligence verdict — sanctions, screening, insolvency, control & financial signals combined.
  • 🔴 Insolvency / collective proceedings on file (1)

AVALUN

Active 5710 7219 Active for 12 years

5710 · RC 799055520 · Active since 2013

B+

Overview

AVALUN is a 5710 registered , France, since 2013. The company operates in the 7219 sector. With reported revenue of 751K EUR in 2021. Its TraceComp score of 75 (B+) indicates solid fundamentals and low apparent risk. With 12 years of operations, the company has an established track record in its market.

Company Information

Registration Number
799055520
Legal Form
5710
Registered
2013-12-01

Financial Profile

Latest filed accounts: FY 2021 · most recent available in public filings

Revenue (2021) 751,369 EUR
Net Income -2,771,346 EUR
Total Assets 5,984,109 EUR
Altman Z -1.70 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

1 officer/director on file — names, roles, appointment & resignation dates.

NameRoleStatus
BIOSYNEX role 73 Current
0

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Insolvency & Collective Proceedings

1 insolvency / collective-proceedings notice on file — most recent published 2025-10-24. A material adverse finding for counterparty and credit risk.

Insolvency notice types, titles, publication dates and official Gazette sources.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 5 patents · 5 active · 5 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue up 44% year-on-year
  • Net loss reported in FY 2021
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.